Genetic Engineering of Probiotic Yeast for Improved Secretion of Antimicrobial Molecules Maryam Al-musawi, Laura Enekegho, Dr. David Stuart UNIVERSITY OF ALBERTA Department of Biochemistry, Faculty of Medicine and Dentistry, University of Alberta



Introduction

- Clostridium perfringens is a pathogenic bacteria that is found in the gut and is the main cause of necrotizing enteritis (NE), which is characterized by small intestinal inflammation.
- It releases toxins that result in symptoms including diarrhea, bloating, and nausea. Broiler chickens are commonly infected with this pathogen as a result of contamination in their feed. Fatality rates are close to 50%, which costs the chicken industry \$6 billion annually.
- The infection has frequently been treated with antibiotics. However, they were prohibited from being included in poultry feeds in 2006 due to increased prevalence of antibiotic-resistant strains.
- Probiotics are live cells that help modulate the digestive environment; they have been found to be an effective alternative to antibiotics. However, their natural defenses against infections are insufficient.
- This study's goal is to precisely kill *C. perfringens* by modifying the probiotic yeast, Saccharomyces boulardii, to better secrete antimicrobial peptides. This was done by removing proteases implicated in the degradation of these antimicrobial peptides.



Proteases degrading the protein



- These mutations were hypothesized to produce yeast with better (C) secretory activity. These mutations were validated by sanger sequencing of the strain's genome.
- (D) An amylase gene was transformed into this newly modified strain to test for increased secretory activity.
- (E) Analysis of this increased activity was done by spotting the yeast cells on starch plates and observing halo formations from starch digestion.

Results

shi 5 yr shi

Mutagenesis of S. Boulardii by CRISPR-Cas9 was Validated by Polymerase



Figures 1.0 - 1.1: To increase secretion of the heterologous endolysin gene, key proteases implicated in degradation of proteins in the yeast secretory pathway were mutagenized using CRISPR-Cas9. A PCR (polymerase chain reaction) was performed to confirm the mutation of the APE1 gene (Fig 1.0) and the YPS1 gene (Fig 1.1).

Sequencing Shows Successful Truncation of Secretion-dampening Genes <u>in S. Boulardii</u>

Fig 2.0: WT APE1 Gene:

.GGTTACGGAAGAATTGCTGTTGCTCCCTAT GGAGGTACACTGAATGAATTGTGGCTAGACA GAGACCTAGGTATTGGTGGTCGCNNNNN..

Fig 2.1: MT APE1 Gene:

.GGTTACGGAAGAATTGCTGTTGCTCCCTAT GGAGGTACACTGAATGAATTGTGGCTAGACA GATAATAGCCNANNNNNNNNNNANNAGN...

Figures 2.0 - 2.3: CRISPR-Cas9 was performed by transforming yeast cells with CRISPR-Cas9 plasmids with gRNAs complementary to proteases' gene regions in the yeast genome. Donor DNAs were then introduced to add premature stop codons to the gene sequences (highlighted in brown in figures 2.1 and 2.3), resulting in a non-functional enzyme. Sanger sequencing of the genome revealed the mutations were successful.

<u>Amylase Activity Shows Improved Secretory Ability of Mutagenized</u> S. boulardii



Figure 3.0 : To validate for increased secretion, an amylase gene was transformed into mutagenized yeast cells and quantified by halo formation on starch plates. Cells included wild-type S. boulardii, $\Delta PRB1 \Delta PEP4$ S. boulardii and $\Delta PRB1 \Delta PEP4 \Delta APE1 \Delta YPS1$ S. boulardii. The transformed cells were grown on synthetic media plates and colonies that appeared were patched and grown in synthetic broth. Serial dilutions of the cultures were made and plated on 2% starch (and 0.5% dextrose) plates to evaluate improved amylase activity.



Fig 2.2: WT YPS1 Gene:

..CCAAGTTCGTCAAGTTGCCCTTTCATAAGCTT TACGGGGACTCGCTAGAAAATGTGGGAAGCGA CAAAAAACCGGAAGTACGCCTATTGAAGAGG..

Fig 2.3: MT YPS1 Gene:

..CCAAGTTCGTCAAGTTGCCCTTTCATAAGCT TTACGGGGACTCGCTAGAAAATGTGGGAAGCG ACAAAAAACCGGAAGTATAATAGCCGACTTAT.



 Utilized CRISPR- Created muta Verification throu
 Confirmed su Knockout of p Strategic deletion Purposeful restricted
 Resulted in a Significance of th Highlights the strains.
 Putting nanoby the gut. Developing a perfringens to be set to be set
Figure 4.0: Agarose gel E showing newly plasmids (shown kb) for the name
 A subclinical ch gavaged for C. supplemented necrotizing enter
growth-pr
growth-pr
 growth-pr antibiotic Cruz, K.C, Enekegho, L. O., & Stuart, <i>Bioengineered Probiotics: Synt</i> https://doi.org/10.3389/fbioe.20 Durmusoglu, D., Al'Abri, I. S., Collins Probiotic Saccharomyces boula Graf, A., Dragosits, M., Gasser, B., & I https://doi.org/10.1111/j.1567-1 Idiris, A., Tohda, H., Kumagai, H., & T <i>Biotechnology</i>, <i>86</i>(2), 403–417 Kiu, R., & Hall, L. J. (2018). An updat https://doi.org/10.1038/s41426- Liu, Z., Liu, L., Österlund, T., Hou, J., Saccharomyces cerevisiae by In McMahon, C., Baier, A. S., Pascolutti, (2018). Yeast surface display pl https://doi.org/10.1038/s41594- Wang, Y., Li, X., Chen, X., & Siewers,
 growth-pr antibiotic Cruz, K.C, Enekegho, L. O., & Stuart, <i>Bioengineered Probiotics: Synt</i> https://doi.org/10.3389/fbioe.20 Durmusoglu, D., Al'Abri, I. S., Collins Probiotic Saccharomyces boula Graf, A., Dragosits, M., Gasser, B., & I https://doi.org/10.1111/j.1567-1 Idiris, A., Tohda, H., Kumagai, H., & T <i>Biotechnology</i>, <i>86</i>(2), 403–417 Kiu, R., & Hall, L. J. (2018). An updat https://doi.org/10.1038/s41426- Liu, Z., Liu, L., Österlund, T., Hou, J., Saccharomyces cerevisiae by In McMahon, C., Baier, A. S., Pascolutti, (2018). Yeast surface display pl https://doi.org/10.1038/s41594- Wang, Y., Li, X., Chen, X., & Siewers,
Fed positi growth-pr antibiotic

Conclusions

- R-Cas9 technology to engineer a distinct variant of S. boulardii: ant strains by deleting $\Delta APE1$ and $\Delta YPS1$ genes.
- igh plating experiments:
- uccessful expression of amylase gene in modified S. boulardii.
- proteases shows increased secretion of heterologous genes.
- ns of crucial protease genes within the yeast secretory pathway:
- emoval of non-essential protease genes.
- noteworthy improvement in heterologous amylase secretion.
- the findings:
- ne potential for refined protein secretion pathways in engineered yeast

Future Directions

body in yeast capable of blocking *C. perfringens* adhesion to

- nanobody library to find potential higher binders to C. o block its adhesion to the intestines.
- lectrophoresis v constructed own around 10 nobody library.

Fig 4.0; A11N A11N Y10N Y10N V14N V14N G16N G16N 58°C 60°C 58°C 60°C 58°C 60°C 58°C 60°C



- hallenge model to be established using broiler chickens perfringens colonization. Model to see if a diet with our engineered probiotic can better treat the resulting teritis disease.
- romotinc

Fed negative control control diet sans antibiotics



Fed experimental diet: wild-type For engineered S. boulardii expressing endolysin

References

- D.T (2022). Bioengineered Probiotics: Synthetic Biology Can Provide Live Cell Therapeutics for the Treatment of Foodborne Diseases thetic Biology Can Provide Live Cell Therapeutics for the Treatment of Foodborne Diseases, 10.
- S. P., Cheng, J., Eroglu, A., Beisel, C. L., & Crook, N. (2021). In Situ Biomanufacturing of Small Molecules in the Mammalian Gut by Mattanovich, D. (2009). Yeast systems biotechnology for the production of heterologous proteins. FEMS Yeast Research, 9(3), 335–348 364 2009 00507 x
- Cakegawa, K. (2010). Engineering of protein secretion in yeast: strategies and impact on protein production. *Applied Microbiology and* https://doi.org/10.1007/s00253-010-2447-0 e on the human and animal enteric pathogen Clostridium perfringens. Emerging Microbes & Infections, 7(1), 1–15.
- Huang, M., Fagerberg, L., Petranovic, D., Mathias Uhlén, & Nielsen, J. (2014). Improved Production of a Heterologous Amylase in verse Metabolic Engineering. Applied and Environmental Microbiology, 80(17), 5542-5550. https://doi.org/10.1128/aem.00712-14 R., Wegrecki, M., Zheng, S., Ong, J. X., Erlandson, S. C., Hilger, D., Rasmussen, S. G. F., Ring, A. M., Manglik, A., & Kruse, A. C. atform for rapid discovery of conformationally selective nanobodies. Nature Structural & Molecular Biology, 25(3), 289–296.
- , V. (2022). CRISPR/Cas9-mediated point mutations improve α-amylase secretion in Saccharomyces cerevisiae. Fems Yeast Research. emsyr/foac033

cknowledgements

Sponsorship:

k PI: art

`S: atla Karla Cristina Cruz Kana Oshima

New Frontiers in Research Fund Fonds Nouvelles frontières en recherche





Andrea Macyk-Davey & Robert Davey

